Pete Strong

Dr. Pete Strong

Chief Scientific Officer and Cofounder

Pete Strong is Pulmocide’s Chief Scientific Officer and Cofounder. Pete’s pharmaceutical industry career from 1980 to 2003 was spent at Glaxo, GlaxoWellcome, and GlaxoSmithKline, with a focus on respiratory drug discovery and development, ending as VP of Strategy and Operations, at RI CEDD, where he worked on the discovery and development of the novel inhaled, once-daily steroid, beta-agonist, and anti-muscarinic, which make up Trelegy Ellipta. Pete cofounded RespiVert in 2007 and stayed with the company through its acquisition in 2010 by Centocor Ortho Biotech (J&J). Pete was a member of the small team that licensed the appropriate RespiVert intellectual property rights to TopiVert Ltd, leading to the successful Series A funding of that company. Pete then cofounded Pulmocide Ltd. in 2013, where he co-invented PC945/opelconazole and coauthored a series of publications describing its properties.

Pete has a B.A. in biochemistry from York University and a Ph.D. in biochemistry from the University of Leeds.

Scroll to Top